ATE549032T1 - Adjuvanzverbindungen zur verbesserung von immunreaktionen auf polynukleotid-basierten impfstoffen - Google Patents

Adjuvanzverbindungen zur verbesserung von immunreaktionen auf polynukleotid-basierten impfstoffen

Info

Publication number
ATE549032T1
ATE549032T1 AT08006254T AT08006254T ATE549032T1 AT E549032 T1 ATE549032 T1 AT E549032T1 AT 08006254 T AT08006254 T AT 08006254T AT 08006254 T AT08006254 T AT 08006254T AT E549032 T1 ATE549032 T1 AT E549032T1
Authority
AT
Austria
Prior art keywords
polynucleotide
adjuvance
compounds
improvement
immune responses
Prior art date
Application number
AT08006254T
Other languages
English (en)
Inventor
Carl J Wheeler
Original Assignee
Vical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vical Inc filed Critical Vical Inc
Application granted granted Critical
Publication of ATE549032T1 publication Critical patent/ATE549032T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/802—Virus-based particle
AT08006254T 1999-03-26 2000-03-24 Adjuvanzverbindungen zur verbesserung von immunreaktionen auf polynukleotid-basierten impfstoffen ATE549032T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12634099P 1999-03-26 1999-03-26

Publications (1)

Publication Number Publication Date
ATE549032T1 true ATE549032T1 (de) 2012-03-15

Family

ID=22424291

Family Applications (3)

Application Number Title Priority Date Filing Date
AT00919777T ATE272410T1 (de) 1999-03-26 2000-03-24 Adjuvanszusammensetzungen zur erhöhung der immunantwort auf polynukleotid-basierende impfstoffe
AT08006254T ATE549032T1 (de) 1999-03-26 2000-03-24 Adjuvanzverbindungen zur verbesserung von immunreaktionen auf polynukleotid-basierten impfstoffen
AT04014973T ATE397942T1 (de) 1999-03-26 2000-03-24 Adjuvanszusammensetzungen zur erhöhung der immunantwort bezüglich polynukleotid-basierenden impfstoffen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT00919777T ATE272410T1 (de) 1999-03-26 2000-03-24 Adjuvanszusammensetzungen zur erhöhung der immunantwort auf polynukleotid-basierende impfstoffe

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT04014973T ATE397942T1 (de) 1999-03-26 2000-03-24 Adjuvanszusammensetzungen zur erhöhung der immunantwort bezüglich polynukleotid-basierenden impfstoffen

Country Status (10)

Country Link
US (7) US6586409B1 (de)
EP (2) EP1955709B1 (de)
JP (2) JP4800485B2 (de)
AT (3) ATE272410T1 (de)
CA (1) CA2365416C (de)
DE (2) DE60012711T2 (de)
DK (1) DK1459766T3 (de)
ES (1) ES2308069T3 (de)
HK (1) HK1121382A1 (de)
WO (1) WO2000057917A2 (de)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105574B1 (en) 1999-03-26 2006-09-12 Vical Incorporated Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
US5641665A (en) * 1994-11-28 1997-06-24 Vical Incorporated Plasmids suitable for IL-2 expression
US20020088014A1 (en) * 1996-05-31 2002-07-04 Xiangming Fang Minimal adenovirus mediated recombinant vaccine
EP1987845B1 (de) * 1997-11-20 2012-03-21 Vical Incorporated Behandlung von Krebs mithilfe Cytokin-exprimierender Polynukleotide und Zusammensetzungen dafür
ATE272410T1 (de) 1999-03-26 2004-08-15 Vical Inc Adjuvanszusammensetzungen zur erhöhung der immunantwort auf polynukleotid-basierende impfstoffe
US7078388B2 (en) * 2000-01-21 2006-07-18 Merial DNA vaccines for farm animals, in particular bovines and porcines
WO2001080897A2 (en) * 2000-04-21 2001-11-01 Vical Incorporated Compositions and methods for in vivo delivery of polynucleotide-based therapeutics
US20030162733A1 (en) * 2000-11-27 2003-08-28 Haynes Joel R. Nucleic acid adjuvants
GB0210538D0 (en) * 2002-05-08 2002-06-19 Univ London Lipids and gene delivery
US7598421B2 (en) 2002-05-08 2009-10-06 Ucl Biomedica Plc Materials for the delivery of biologically-active material to cells
WO2004024067A2 (en) * 2002-09-10 2004-03-25 Vical Incorporated Codon-optimized polynucleotide-based vaccines against bacillus anthracis infection
WO2004058166A2 (en) * 2002-12-23 2004-07-15 Vical Incorporated Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection
EP1578193A4 (de) * 2002-12-23 2011-06-15 Vical Inc Gefriertrocknungsverfahren für nukleinsäure-/blockcopolymer-/kationtensid-komplexe
CA2508281C (en) 2002-12-23 2011-08-09 Vical Incorporated Method for producing sterile polynucleotide based medicaments
US8080642B2 (en) 2003-05-16 2011-12-20 Vical Incorporated Severe acute respiratory syndrome DNA compositions and methods of use
US7504243B2 (en) 2004-03-19 2009-03-17 The United States Of America As Represented By The Department Of Health And Human Services Methods for the production of biliverdin
US7303881B2 (en) * 2004-04-30 2007-12-04 Pds Biotechnology Corporation Antigen delivery compositions and methods of use
CA2566355C (en) * 2004-05-18 2014-04-15 Vical Incorporated Influenza virus vaccine composition and methods of use
CN101151049A (zh) * 2004-06-15 2008-03-26 纽约血液中心有限公司 旋盘尾丝虫的天然产物的佐剂和免疫加强性能
US20060134221A1 (en) * 2004-12-03 2006-06-22 Vical Incorporated Methods for producing block copolymer/amphiphilic particles
AU2006203985A1 (en) * 2005-01-05 2006-07-13 Philadelphia Health And Education Corporation Delivery vehicles, bioactive substances and viral vaccines
DK1858920T3 (en) 2005-02-18 2016-02-29 Glaxosmithkline Biolog Sa PROTEINS AND NUCLEIC ACIDS FROM MENINGITIS / SEPSIS-ASSOCIATED ESCHERICHIA COLI
ATE552267T1 (de) 2005-02-18 2012-04-15 Novartis Vaccines & Diagnostic Immungene von uropathogenen escherichia coli
US7957507B2 (en) 2005-02-28 2011-06-07 Cadman Patrick F Method and apparatus for modulating a radiation beam
AU2006236905B2 (en) 2005-04-15 2010-06-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
US8232535B2 (en) 2005-05-10 2012-07-31 Tomotherapy Incorporated System and method of treating a patient with radiation therapy
JP2009502251A (ja) 2005-07-22 2009-01-29 トモセラピー・インコーポレーテッド 放射線治療システムによって送達された線量を評価するシステム及び方法
US8442287B2 (en) 2005-07-22 2013-05-14 Tomotherapy Incorporated Method and system for evaluating quality assurance criteria in delivery of a treatment plan
AU2006272742A1 (en) 2005-07-22 2007-02-01 Tomotherapy Incorporated System and method of delivering radiation therapy to a moving region of interest
KR20080049716A (ko) 2005-07-22 2008-06-04 토모테라피 인코포레이티드 치료 계획의 전달과 관련된 퀄리티 보증 기준을 평가하는방법 및 시스템
CN101267768A (zh) 2005-07-22 2008-09-17 断层放疗公司 对接受放射疗法的患者的呼吸时相进行检测的系统和方法
WO2007014090A2 (en) 2005-07-23 2007-02-01 Tomotherapy Incorporated Radiation therapy imaging and delivery utilizing coordinated motion of gantry and couch
ES2792398T3 (es) 2005-11-04 2020-11-11 Seqirus Uk Ltd Vacunas adyuvantadas con antígenos de no virión preparadas a partir de virus de la gripe cultivados en cultivo celular
AU2007239095B2 (en) 2006-01-09 2012-05-03 The Regents Of The University Of California Immunostimulatory combinations for vaccine adjuvants
WO2007085969A2 (en) 2006-01-27 2007-08-02 Novartis Vaccines And Diagnostics Gmbh & Co Kg Influenza vaccines containing hemagglutinin and matrix proteins
EP2004226A1 (de) 2006-03-24 2008-12-24 Novartis Vaccines and Diagnostics GmbH & Co. KG Lagerung von grippeimpfstoffen ohne kühlung
SG173336A1 (en) 2006-03-31 2011-08-29 Novartis Ag Combined mucosal and parenteral immunization against hiv
ATE522541T1 (de) 2006-06-09 2011-09-15 Novartis Ag Bakterielle adhäsine konformere
AU2007275047A1 (en) 2006-07-20 2008-01-24 University Of Washington Compositions and methods for vaccinating against HSV-2
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
CA2659552A1 (en) 2006-08-16 2008-02-21 Novartis Ag Immunogens from uropathogenic escherichia coli
US20100010199A1 (en) 2006-09-11 2010-01-14 Novartis Ag Making influenza virus vaccines without using eggs
EP2121942A2 (de) * 2006-12-04 2009-11-25 Vical Incorporated Kartuschenimpfstoffe mit linearer expression
WO2008068631A2 (en) 2006-12-06 2008-06-12 Novartis Ag Vaccines including antigen from four strains of influenza virus
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
US20080274137A1 (en) * 2007-05-02 2008-11-06 Jean Christophe Francis Audonnet DNA plasmids having improved expression and stability
UA100692C2 (ru) 2007-05-02 2013-01-25 Мериал Лимитед Днк-плазмиды, имеющие повышенную экспрессию и стабильность
EP2167480A2 (de) * 2007-05-23 2010-03-31 Vical Incorporated Zusammensetzungen und verfahren zur verbesserung der immunreaktionen auf impfstoffe
WO2009005917A2 (en) * 2007-05-29 2009-01-08 Vical Incorporated Methods of treating measles infectious disease in mammals
PL2185191T3 (pl) 2007-06-27 2013-02-28 Novartis Ag Szczepionki przeciwko grypie o małej zawartości dodatków
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
RU2530555C2 (ru) 2008-04-17 2014-10-10 ПиДиЭс БАЙОТЕКНОЛОДЖИ КОРПОРЭЙШН Стимуляция иммунного ответа энантиомерами катионных липидов
US8585505B2 (en) 2008-12-15 2013-11-19 Tetris Online, Inc. Inter-game interactive hybrid asynchronous computer game infrastructure
WO2010130374A1 (en) * 2009-05-14 2010-11-18 Bayer Animal Health Gmbh Enhanced immune response in avian species
AR077757A1 (es) 2009-07-15 2011-09-21 Novartis Ag Composiciones de proteinas de fusion del virus sincicial respiratorio (rsv) y metodos para su preparacion
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
MX2013001613A (es) 2010-08-09 2013-04-22 Cyvax Inc Métodos y composiciones para prevenir una afección.
ES2722204T3 (es) 2010-12-22 2019-08-08 Bayer Ip Gmbh Respuesta inmune mejorada en especies bovinas
EP4144368A1 (de) 2011-01-26 2023-03-08 GlaxoSmithKline Biologicals S.A. Rsv-immunisierungstherapie
ES2782119T3 (es) 2011-05-13 2020-09-10 Glaxosmithkline Biologicals Sa Antígenos de F de prefusión del VRS
US20130071403A1 (en) 2011-09-20 2013-03-21 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
WO2013106558A1 (en) * 2012-01-10 2013-07-18 Merial Limited Lipid based adjuvants for dna - plasmid vaccines
WO2013108272A2 (en) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
AU2013317805B2 (en) 2012-09-21 2018-07-26 Pds Biotechnology Corporation Improved vaccine compositions and methods of use
CN107469240B (zh) 2013-02-26 2020-04-21 安科锐公司 多叶准直器和用于准直治疗放射束的系统
BR112016019837A2 (pt) 2014-02-28 2017-10-17 Bayer Animal Health Gmbh plasmídeos imunoestimuladores
AU2016302436B2 (en) 2015-07-31 2022-03-03 Bayer Animal Health Gmbh Enhanced immune response in porcine species
EP3374496A4 (de) 2015-11-13 2019-07-10 PDS Biotechnology Corporation Lipide als synthetische vektoren zur verbesserung der antigenverarbeitung und präsentation ex-vivo in der dendritischen zelltherapie
CA3006779A1 (en) 2015-12-09 2017-06-15 Admedus Vaccines Pty Ltd Immunomodulating composition for treatment
CN105483076B (zh) * 2015-12-23 2019-01-25 中国科学院生物物理研究所 一种脂肪体的制备方法及其应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6867195B1 (en) 1989-03-21 2005-03-15 Vical Incorporated Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected
US5676954A (en) 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US6706694B1 (en) 1990-03-21 2004-03-16 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate
US6228844B1 (en) 1991-11-12 2001-05-08 Vical Incorporated Stimulating vascular growth by administration of DNA sequences encoding VEGF
US20030186913A1 (en) 1990-03-21 2003-10-02 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US7105574B1 (en) * 1999-03-26 2006-09-12 Vical Incorporated Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
ATE301201T1 (de) 1993-06-07 2005-08-15 Vical Inc Für die gentherapie verwendbare plasmide
IL113817A (en) 1994-06-30 2001-03-19 Merck & Co Inc Polynucleotide for vaccination against the umbilical cord virus
US5641665A (en) * 1994-11-28 1997-06-24 Vical Incorporated Plasmids suitable for IL-2 expression
US5705385A (en) * 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
IL122290A0 (en) 1995-06-07 1998-04-05 Inex Pharmaceuticals Corp Lipid-nucleic acid complex its preparation and use
CA2237316C (en) * 1995-11-30 2012-06-26 Vical Incorporated Complex cationic lipids
US5994317A (en) 1996-04-09 1999-11-30 Vical Incorporated Quaternary cytofectins
US5861397A (en) 1996-10-03 1999-01-19 Vical Incorporated Piperazine based cytofectins
US6235310B1 (en) * 1997-04-04 2001-05-22 Valentis, Inc. Methods of delivery using cationic lipids and helper lipids
EP1987845B1 (de) * 1997-11-20 2012-03-21 Vical Incorporated Behandlung von Krebs mithilfe Cytokin-exprimierender Polynukleotide und Zusammensetzungen dafür
ATE272410T1 (de) * 1999-03-26 2004-08-15 Vical Inc Adjuvanszusammensetzungen zur erhöhung der immunantwort auf polynukleotid-basierende impfstoffe
US6696424B1 (en) 1999-05-28 2004-02-24 Vical Incorporated Cytofectin dimers and methods of use thereof
WO2001080897A2 (en) 2000-04-21 2001-11-01 Vical Incorporated Compositions and methods for in vivo delivery of polynucleotide-based therapeutics
WO2002072019A2 (en) 2001-03-13 2002-09-19 Vical Incorporated Interferon-beta polynucleotide therapy for autoimmune and inflammatory diseases
CN100354050C (zh) 2002-01-28 2007-12-12 杰富意钢铁株式会社 涂装钢板的制造方法
WO2004024067A2 (en) * 2002-09-10 2004-03-25 Vical Incorporated Codon-optimized polynucleotide-based vaccines against bacillus anthracis infection
CA2508281C (en) 2002-12-23 2011-08-09 Vical Incorporated Method for producing sterile polynucleotide based medicaments
EP1578193A4 (de) 2002-12-23 2011-06-15 Vical Inc Gefriertrocknungsverfahren für nukleinsäure-/blockcopolymer-/kationtensid-komplexe
WO2004058166A2 (en) 2002-12-23 2004-07-15 Vical Incorporated Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection
US8080642B2 (en) * 2003-05-16 2011-12-20 Vical Incorporated Severe acute respiratory syndrome DNA compositions and methods of use

Also Published As

Publication number Publication date
DE60012711T2 (de) 2005-08-18
ES2308069T3 (es) 2008-12-01
US20140065189A1 (en) 2014-03-06
EP1955709A3 (de) 2008-08-20
ATE397942T1 (de) 2008-07-15
HK1121382A1 (en) 2009-04-24
CA2365416A1 (en) 2000-10-05
US7582613B2 (en) 2009-09-01
EP1165140B1 (de) 2004-08-04
DE60039198D1 (de) 2008-07-24
ATE272410T1 (de) 2004-08-15
US20080145387A1 (en) 2008-06-19
WO2000057917A3 (en) 2001-01-04
DE60012711D1 (de) 2004-09-09
DK1459766T3 (da) 2008-10-13
EP1955709B1 (de) 2012-03-14
JP4800485B2 (ja) 2011-10-26
JP2002540173A (ja) 2002-11-26
US20030191082A1 (en) 2003-10-09
US8415317B2 (en) 2013-04-09
WO2000057917A2 (en) 2000-10-05
JP2007176954A (ja) 2007-07-12
CA2365416C (en) 2011-06-14
US20080213306A1 (en) 2008-09-04
US6586409B1 (en) 2003-07-01
US20110165197A1 (en) 2011-07-07
EP1165140A2 (de) 2002-01-02
US20130295139A1 (en) 2013-11-07
EP1955709A2 (de) 2008-08-13

Similar Documents

Publication Publication Date Title
ATE549032T1 (de) Adjuvanzverbindungen zur verbesserung von immunreaktionen auf polynukleotid-basierten impfstoffen
IL150602A0 (en) Proteosome influenza vaccine
AR014182A1 (es) Composiciones de vacunas utiles para el tratamiento o profilaxis de tumores o lesiones inducidas por hpv; procedimiento para prevenir o tratar tumoresinducidos por hpv y procedimiento para preparar dichas composiciones
PT1487485E (pt) Adjuvantes de imidazoquinolina para vacinas de adn
FI20011593A (fi) Immunologinen adjuvanttiyhdiste
GB2386072A (en) Novel vaccine
ATE511855T1 (de) Adjuvansformulierung zur scheimhaut-applikation
BR0111834A (pt) Composições adjuvante e imunogênica, e, método para eliciar uma resposta imune a um antìgeno
ATE377428T1 (de) Rotavirus-impfstoff
ATE284613T1 (de) Polynukleotid-impfstoff-formulierungen
PT1112747E (pt) Vacina de salmonella que nao induz anticorpos contra flagelina ou flagelos
AU2001284354A1 (en) Immunological adjuvant compounds, compositions, and methods of use thereof
DK1074266T3 (da) Levende svækkede bakterier til anvendelse i vaccine
FR2809960B1 (fr) Composition adjuvante de la reponse immunitaire comprenant la proteine fha ou un fragment de la proteine fha sous forme libre, et composition immunogene ou vaccinale contenant une telle composition adjuvante
DK1227840T3 (da) Adjuverede, genetiske vacciner
ATE318300T1 (de) Isolierte stämme von staphylococcus aureus und daraus hergestellte impfstoffe
DK1490100T3 (da) Kombinerede DNA/proteinvaccinepræparater
DE69942161D1 (de) Genetische Adjuvanz-Impfstoffe